Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

NCT06679985 is registered in ClinicalTrials.gov with Coherus Oncology, Inc. as lead sponsor.

NCT NCT06679985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06679985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Lead sponsor
Coherus Oncology, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 20, 2024
Completion date
September 30, 2027
Enrollment
72 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma